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Abstract
Background: Surgery has become heavily dependent on accurate imaging in the assessment and
treatment of suspected or confirmed intra-abdominal malignancy. Positron emission tomography-
computed tomography (PET-CT) fuses uptake of a radiotracer combined with CT images to assess both
functional tissue activity and anatomical detail. Since its introduction it has offered new ways of treating
gastrointestinal cancers.
Methods: The review analyses the present literature regarding the use of PET-CT in the assessment,
diagnosis, staging and treatment of hepatobiliary malignancies.
Results: PET-CT is widely used in pre-operative tumours staging for colorectal liver metastases. There
is convincing data that it may also be applicable for neuroendocrine tumours, assessment of indetermi-
nate pancreas lesions and clinical drug trials. PET-CT is of limited value in hepatocellular cancers,
although new techniques in dual-tracer PET-CT may change this.
Conclusion: Knowledge of the strengths and limitations of PET-CT is important for all surgeons man-
aging cancer of the hepatobiliary system. More clinical data are required on PET-CT, particularly its effect
on long-term survival in PET-CT-staged patients undergoing resection.
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Introduction
Surgery has become heavily dependent on accurate imaging in
the assessment and treatment of suspected or confirmed intra-
abdominal malignancy. The role of cross-sectional imaging in this
context can be multiple and includes the diagnosis of malignancy,
staging of confirmed cancers, assessment of response to treat-
ment, planning of neoadjuvant treatment (such as radiotherapy)
and surveillance both pre- and post-operatively (Fig. 1). Unlike
conventional imaging, positron emission tomography (PET)
combined with computed tomography (CT) (PET-CT) allows an
evaluation of the physiological and biochemical processes under-
lying malignant disease and consequently offers a new perspective
in the treatment of intra-abdominal malignancies. The majority
of the literature regarding PET-CT is published in radiological
journals; however, surgeons as one of the main clients of cross-
sectional imaging must be familiar with the concepts, strengths
and weaknesses of advances such as PET-CT. The focus of this
review will be to update the reader regarding the current evidence
of how PET-CT is employed in the management of hepatobiliary
cancers.
Positron emission tomography
Positron emission tomography is based on detecting positrons
released by radiopharmaceuticals, known as tracers. A positron is
a positively charged particle emitted from a parent nucleus. These
tracers are bound to molecules which are involved in normal or
pathological processes. The uptake of these functional molecules
(known as probes) can then be detected and quantified. The first
PET scans were reported in the 1980s and since then, their use in
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both research and practical applications has rapidly expanded.1
The most widely used molecule is 18Flurodeoxyglucose (18F-FDG)
which is a glucose analogue actively transported into all living
cells. After intra-cellular transportation and phosphorylation, 18F-
FDG is locked within the cell, as (unlike glucose) it is unable to
undergo further metabolism.Cellular uptake of 18F-FDG is related
to expression of glucose transport membranes within the cell
membrane. These proteins are expressed in all cells but are over-
expressed in malignant tissue leading to intracellular accumula-
tion of 18F-FDG which can be visualized2 using a gamma camera
(Fig. 2). Other tissues such as brown fat, skeletal muscle and
inflamed tissue also demonstrate increased uptake of 18F-FDG3
and may lead to false-positive results. Depending on the focus of
investigation, other probes can be employed, for example 18F-
fluoride is used for PET scans where measurement of increased
bone activity (for the detection of bony metastases) is required.4
PET-CT fusion
The combination of conventional cross-sectional imaging with
PET scanning enables both functional and anatomical information
regarding a patient to be fused into one study.With PET images in
isolation, it may be impossible to accurately localize an area of
increased activity as a result of the absence of identifiable anatomi-
cal structures. With a normal CT scan, the intensity of the images
seen correlates with the structure and visceral density of the exam-
ined organ. However, in PET-CT the image intensity is dependent
on the functional activity of the tissue taking up the radiotracer. In
addition to PET-CT, other promising fusion imaging includes
single-photon emission tomography (SPET) or PET/magnetic
resonance imaging (MRI). SPET is similar to PET-CT with the
main difference being the utilization of radiopharmaceutical agent
employed; SPET employing gamma ray-emitting tracers which are
detected by a gamma camera. In addition to improving the clarity
of images, PET-CT fusion offers other advantages including a
shorter scan time (by reducing the period required to correct for
changes in tissue electron density) leading to increased patient
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Figure 2 Schematic overview of positron emission tomography (PET) of malignant tissue
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throughput and reducing the amount of radiotracer used, thereby
reducing the imaging cost per patient.5,6
Special considerations in PET-CT
The advent of PET-CT fusion has required modifications to
CT and PET protocols in order to achieve clarity and precise
overlap of images. Contrast material artefacts are possible, par-
ticularly in thoracic veins, and as a consequence some centres will
employ a caudocranial image acquisition protocol rather than the
traditional craniocaudal sequence.7 Alternatively, a saline flush is
administered after contrast injection.7 Full-body PET-CT images
will typically only cover from the head to the upper thighs, espe-
cially when used in the investigation of abdominal malignancies.
For melanomas and soft tissue tumours, the lower limbs will be
included in the imaging protocol. Intense tracer uptake within the
brain limits the usefulness of PET scanning in detecting cerebral
abnormalities and for this reason the CT component of the images
may be of greater diagnostic value.
Shallow breathing is generally permitted during both
PET and CT image acquisition. However, this may lead to
problems in accurate image co-registration. Fusion of images
has been shown to be most accurate if the CT is acquired
during normal expiration8 and this would be the goal in
‘whole-body’ CT scans but may be difficult to achieve. Breath-
holding during scanning of the lower lungs and upper abdominal
viscera may be an adequate compromise. For small pulmonary
lesions, particularly if located around the diaphragm, breathing
artefacts may hamper lesion detection. Additional low-dose CT,
during maximum inspiration or expiration, may be included after
the standard PET-CT to improve image clarity.7 However, this is at
increased radiation exposure, and there is no current consensus of
opinion on the adoption of such techniques.
After 18F-FDG administration, patient activity is limited
for up to 20 min afterwards to avoid excessive uptake of tracer into
skeletal tissue.9 Accumulation of tracer in the bladder may hamper
accurate visualization of pelvic organs and patients are encour-
aged to void prior to their scan, some centres may also employ
catheterization, although this is not routine practice.9 Intravenous
and oral contrast can be used to optimize the diagnostic accuracy
of the CT component of the scan. Scanning times will inevitably
vary according to the model of scanner and the scanning protocol
used. On average, CT studies will take about 60 to 70 s and the
PET component 30 to 45 min.9
Standardized uptake value (SUV) is a semi-quantitative assess-
ment of tracer uptake from the PET image. SUV from normal
tissue is predictably less than that of malignant lesions. Base-line
SUV is a useful measurement when using PET-CT to monitor
tumour response to treatment. A decrease in SUV can be corre-
lated with reduced physiological activity within a cancer, thus
corresponding to response to treatment.9 As SUV can vary accord-
ing to the time from tracer injection to image acquisition, stan-
dardization of this is important.10
Research applications of PET-CT
PET-CT, as yet, has a small role in the drug development; however,
it has shown considerable promise in its applicability to assess
drug metabolism, distribution and tumour response to new
compounds. At present, the bulk of the literature describes PET in
isolation, but with the increasing number of PET-CT scanners,
particularly in clinical practice, it seems likely that fusion images
will also be employed in the future. Utilization of PET in drug
trials has been largely confined to human clinical trials, but in
small animal models PET has also be employed. The resolution of
scanners used in pre-clinical animal trials is of necessity greater
than those used in a clinical setting (by up to four-fold). PET-CT
has several potential advantages over conventional assessment of
tumour response to treatment in murine models, as the CT com-
ponent can be used to measure tumour size and the PET scan can
correlate changes in size with reduction in tumour activity. CT has
been shown to be more accurate than standard measurements in
assessing tumour size11 but this increased accuracy is gained at a
greater cost than conventional calliper measurement. PET alone
has been used in a number of animal models to measure immune
response, tumour hypoxia and gene expression after experimental
treatment.12–14
Patient selection for drug trials
Many novel anti-tumour agents specifically target cell surface
receptors, the expression of which may vary between individuals.
Patients with a low receptor expression are unlikely to benefit
from such novel agents and hence PET can be a means of selecting
those who are most likely to respond to chemotherapy. At present
no data exists in the literature concerning the application of
PET-CT in this context for hepatobiliary malignancies. However,
PET imaging has been used in assessing over-expression of
P-glycoprotein (associated with drug-resistant tumours) in the
context of preclinical studies,15 thereby avoiding the invasive use
of biopsies in determining tumour phenotype.
Metabolism and drug distribution
As discussed earlier, the choice of compound to which a
radiotracer is bound to can be varied depending on the physi-
ological or biochemical process which needs to be studied. By
binding a radiotracer to an active pharmaceutical compound, the
distribution of that drug and its uptake within the target tumour
can be monitored. It would seem almost inevitable that these
pharmacokinetic studies will evolve to the addition of CT to
current PET imaging, thereby increasing the accuracy of localizing
the uptake of chemotherapeutic compounds in normal versus
malignant tissue. Compounds studied using PET imaging alone
include fluorouracil, paclitaxel and N-cisplatin.16–18
Tumour response
Assessment of tumour response to novel chemotherapy regimens
is a vital part of clinical drug trials. This allows for accurate
6 HPB
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evaluation of the efficacy of the tested drug and can also be used
to exclude patients who are not responding and may be experi-
encing troublesome side-effects. Conventional assessment
includes CT monitoring of tumour size, spread and serum
tumour markers. However, a reduction in tumour size may not be
evident immediately and gives little information of drug efficacy
in tumours where growth is stabilized but tumour regression has
not been achieved. Some new chemotherapy compounds act in a
cytostatic rather than cytotoxic fashion, further compounding the
problem in using tumour size alone as a measurement of drug
impact.19
By acting as a marker of tumour physiology and activity,
PET-CT adds a new dimension to clinical drug trials. An example
of the use of PET-CT in this setting is in the development of the
tyrosine kinase receptor inhibitor, imatinib, used for the treatment
of gastrointestinal stromal tumours (GISTs). In this context,
PET-CT was shown to predict response to therapy, as early as 24 h
after treatment.20 Early exclusion of non-viable drugs can, there-
fore, be achieved and so increasing the throughput of tested com-
pounds. In addition, PET-CT can accurately stage malignancies,
revealing occult metastases not visualized on conventional CT
imaging, allowing a more accurate evaluation of drug response in
relation to tumour burden.
PET-CT and colorectal liver
metastases assessment
The role of PET-CT in the evaluation of colorectal hepatic
metastases lies predominantly in tumour staging, specifically to
detect extrahepatic disease or occult intrahepatic metastases not
evident on conventional scanning. In the context of planned liver
resection, extrahepatic metastases are considered a contraindica-
tion to surgery and detecting occult disease spares these patients
an unnecessary laparotomy. PET-CT fusion has been shown to
consistently improve on tumour staging when compared with
PET alone21,22 or if compared with parallel evaluation of indepen-
dently acquired CT and PET images.23 Other potential applica-
tions of PET-CT include localization of intrahepatic tumours
for ablative or resection therapy, surveillance and assessment to
tumour response to intervention. At present, no studies are
evident detailing the use of PET-CT as surveillance after colorectal
liver metastases (CLM) resection.
Tumour staging
Table 1 displays current reports regarding the use of PET-CT of
patients under consideration for liver resection with suspected
colorectal liver metastases (CLM).24–28 The data shows that
PET-CT is more accurate in the detection of extra-hepatic disease
than CT alone and at least as accurate as CT in the detection of
intra-hepatic disease. MRI is both accurate and sensitive in the
detection of hepatic metastases with one study demonstrating it to
be better than PET-CT.24 It has been previously shown that sur-
vival of PET-staged patients after hepatic resection is significantly Ta
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improved, which is probably explained by the selection of patients
without occult metastatic disease which becomes clinically
evident at a later date.29 At present, no survival data of PET-CT-
staged patients undergoing liver resection are available in the
literature.
Two studies reviewed reported evidence that pre-operative che-
motherapy reduces the sensitivity of PET-CT in the detection of
colorectal metastases from 93 to 49%.25,26 This may be secondary
to reduced metabolic activity within the metastases and so
reduced SUV compared with background uptake or possibly sec-
ondary to a reduction in the size of the lesion below the resolution
of PET imaging.25 A high rate of PET-CT false positives at the liver
edge, after previous hepatic resection, has also been described
with a resultant specificity of only 60%.25 However, other studies
contradict this, with Selzner reporting a difference in sensitivity
between PET-CT and conventional CT of 100% versus 50%
respectively.26 PET-CT also demonstrates a high sensitivity in the
detection of lung metastases (100%).26
In the absence of long-term survival data on post-operative
PET-CT-staged patients, it is difficult to fully assess the clinical
impact of PET-CT. However, three of the reviewed studies
reported a change in patient management in 10.7% to 21% of
patients.24,26,27 These changes in management included avoidance
of laparotomy, commencement of palliative chemotherapy or
undertaking more extensive surgery than originally planned.24,26,27
While the data regarding PET-CT in staging for CLM is relatively
sparse, one can tentatively assume that conventional imaging such
as MRI or CT are at least comparable (or worse) to PET-CT in the
assessment of hepatic disease, but PET-CT is more useful in the
detection of extrahepatic disease.
Intrahepatic tumour localization for surgery
or ablation
The role of intra-operative ultrasound (IOUS) during liver
surgery has been shown to change the planned surgical proce-
dure in 19% to 65% of patients.30–34 Only one study was found
examining the efficacy of IOUS in patients who had undergone
previous PET-CT as staging.35 While a direct comparison was
not made between PET-CT and IOUS, the addition of IOUS was
found to result in changes in management for 35% of patients
and to improve sensitivity and specificity (in combination with
PET-CT) from 63% and 81%, respectively, to 93% and 89%.35 It
would seem for the time-being that even with PET-CT pre-
operatively, IOUS remains a vital component in the assessment
of CLM.
PET-CT has also been utilized in planning ablative therapies for
unresectable liver lesions, including CLMs. PET-CT is useful in
selecting patients suitable for ablative therapy in that it can reli-
ably exclude extra-hepatic disease. In those patients where disease
is not solely localized to the liver, then systemic chemotherapy
would be a more appropriate form of palliation. After radiofre-
quency ablation, a contrast-enhancing rim is often noted around
the periphery of the ablation site on intra-venous contrast-
enhanced CT imaging.36 These features may make subsequent
follow-up of ablated lesions difficult to assess properly on conven-
tional scanning. PET-CT has been shown to be more accurate
than contrast-enhanced CT in post-ablation surveillance (65% vs.
44%).37 PET-CT may also allow for more accurate localization of
active tumour, hence, maximizing the tumour destruction after
ablation.36,38 In a porcine model, PET-CT was found to be more
accurate than CT alone in guiding and positioning of interven-
tional devices for isodense liver lesions.39 However, these findings
will only apply to liver lesions demonstrating increased 18F-FDG
uptake.
Assessment of chemotherapy response/microspheres
PET-CT has been reported in the assessment of tumour activity
after 90Y microsphere treatment of unresectable CLMs, using
reduction of SUV as compared with baseline levels.40 Reduction in
tumour activity was noted in over 60% of treated tumours at 1
month after treatment.40 These changes occurred before a reduc-
tion in tumour size is evident and before a demonstrable reduc-
tion in CEA levels.40 The small number of patients within the
study (n = 5) precluded any meaningful analysis of whether this
reduction in tumour activity correlated with improved survival,
and as the authors themselves correctly noted, being palliative
treatment histological confirmation of tumour necrosis could not
be obtained in the patients studied. Another report using PET-CT
in the evaluation of bevacizumab and irinotecan given pre-
operatively, was able to obtain histological verification of PET-CT
findings in 85% of treated lesions.41 The authors reported that
PET-CT accurately predicted tumour necrosis in 70% of lesions
versus 35% using CT alone.41
Who to scan?
Despite its value in staging patients prior to consideration of liver
surgery, PET-CT is currently a relatively costly imaging technique
with a paucity in available scanners, even for high volume hepa-
tobiliary centres. These constraints are important in rationalizing
which patients should undergo PET-CT staging. At present, there
appears to be little consensus whether PET-CT should be offered
routinely, or only in those patients where a clinical suspicion of
occult disease is present. For staging of primary lung cancer and
lymphomas, PET-CT has largely become routine staging in most
centres, but more data are needed in the context of colorectal
cancer metastases before any firm recommendations can be made.
At present, despite some centres employing PET-CT for patients
presenting with CLM,26 most units employ PET-CT on a selective
basis. Initial staging will consist of CT and MRI, with PET-CT
employed after discussion at a multidisciplinarymeeting if there is
a suspicion of occult disease not evident on conventional imaging
or to further clarify anomalies seen but not clearly evaluated by
CT or MRI.42
The lack of published data regarding the cost-effectiveness of
PET-CT makes a conclusive evaluation problematic. Data regard-
ing PET in isolation suggested a cost saving of €2,671 per patient
8 HPB
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by avoiding inappropriate exploratory laparotomy in 6.1% of
patients.43 In the small sample of studies examining PET-CT for
CLM, a change in clinical management was evident in approxi-
mately 10% to 20% (Table 1). While this change in management
covered a range of clinical procedures (an itemised breakdown
was not possible from the reported data), for some patients this
entailed avoiding unnecessary laparotomy. One could surmise
that a similar cost saving (or possibly greater cost saving consid-
ering that PET-CT allows for greater patient throughput and
reduced usage of radiotracer than PET) could be obtained with
PET-CT. However, it is possible that this cost saving may not be
immediately apparent.With any developing technology it is likely
that patients with equivocal PET-CTs suggestive of extrahepatic
recurrence may still undergo exploratory surgery to confirm or
refute the findings. This pragmatic approach will doubtless
improve confidence in the validity of the imaging results in the
future and (combined with potential survival benefits in PET-CT-
staged patients undergoing resection) may allow for a full realiza-
tion of projected cost savings.
Inaccuracies in PET-CT
With any imaging modality, the standard of reference used to
confirm that visualized abnormalities are representative of actual
pathology determines the degree of confidence with which one
may interpret reports of sensitivity and specificity.24 The ideal is to
have histological proof that the visualized lesion represents malig-
nancy. In the context of PET-CT in staging of CLMs, all the studies
reviewed used surgical findings (including IOUS and resection) as
part of the standard of reference. However, for patients with a
burden of disease precluding surgical exploration, obtaining his-
tological proof may be problematic both technically and ethically.
All studies reviewed relied on clinical follow-up for a proportion
of the patients who did not undergo surgery. As such, it is impor-
tant to appreciate that this unavoidable flaw underpins all studies
assessing any new diagnostic modality. For this reason, percuta-
neous or intra-operative confirmation of PET-CT positive foci
should be attempted if possible.24
As discussed previously, lesions on the dome of the liver may be
inaccurately localized by PET-CT to right basal lung lesions,
although the incidence of this appears to be very low, being
detected in only 6 out of 300 patients.44 False positives have been
reported at sites of inflammation, including suture granulomas or
suture pedicles,45 or from retained activity within ureters, bladder
or thrombus.46,47 False negatives may occur in patients who have
received previous chemotherapy, cystic lesions, small volume
disease and miliaric peritoneal disease.25,26,47 Delayed PET-CT
scanning may facilitate tumour detection by allowing more time
for 18F-FDG to penetrate hypoxic areas within tumours and accu-
mulate sufficiently to increase SUV above baseline detection.28
Careful scrutiny of the CT component of PET-CT is also essential
in providing further valuable information. It has been previously
shown that independent blinded review of the CT component of
PET-CT images improved sensitivity and specificity from 91.4%
and 63.3% to 98.6% and 100%, respectively.48
PET-CT and diagnosis of colorectal
liver metastases
PET-CT is increasingly being used in the staging and follow-up of
primary colorectal cancer. As a consequence, patients are now
referred for consideration for resection to hepatobiliary units
with liver disease diagnosed on PET-CT. These patients represent
a select group in that extra-hepatic disease will have already been
excluded or been assessed for resectability (for example patients
with pulmonary recurrences). In addition, data from studies
examining evidence of PET-CT efficacy only in the exclusion of
local or extra-hepatic recurrence, adds further information
regarding the ability of PET-CT to detect such extra-hepatic sites
of recurrence as compared with conventional imaging. For these
reasons, an over-view of the use of PET-CT in primary colorectal
cancer is of interest and offers important insights to hepatobiliary
surgery.
The papers reviewed were restricted to those evaluating the
diagnostic application of PET-CT in the staging or surveillance of
primary colorectal cancer. Manuscripts detailing the use of
PET-CT for radiotherapy planning or virtual colonography were
not examined, as this was not relevant to hepatobiliary practice.
The data are summarized in Table 2.49–57 For the most part, the
data show increased sensitivity and specificity of PET-CT in
detecting lymph node disease, hepatic, extra-abdominal and
extrahepatic recurrence/metastases when compared with PET
and/or CT. These observations further support the use of PET-CT
in staging CLMs particularly with regards to the exclusion of
extrahepatic disease prior to resection.
PET-CT and hepatocellular carcinoma
Only 30% to 50% of primary hepatocellular carcinomas (HCC)
demonstrate 18F-FDG uptake above background levels.58 High
levels of glucose-6-phosphatase are found in normal liver and
HCCs leading to dephosphorylation of 18F-FDG, which subse-
quently no longer accumulates in cells and redistributes back into
the circulation. For this reason, PET-CT has limited application in
the evaluation of intra-hepatic HCCs.58 More recently an alterna-
tive tracer (11C- acetate) has been used in conjunction with 18F-
FDG which improves visualization of these lesions.59 The degree
of HCC differentiation determines its relative avidity for one of
the two probe molecules. Well-differentiated HCCs demonstrate
negative uptake on 18F-FDG and positive uptake with 11C-acetate,
while poorly differentiated HCCs display the reverse characteris-
tics. Moderately differentiated HCCs will show a mixed affinity in
various parts of the tumour between the two tracer molecules.59
While this combination of tracers (dual tracer PET-CT) may offer
better imaging of HCCs, its application has not yet been reported
HPB 9
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in PET-CT imaging for intra-hepatic HCCs beyond description in
abstract form.60
The short half-life of 11C-acetate limits its applicability only to
centres with an on-site cyclotron. An alternative probe is the com-
pound 18F-Fluorocholine. Choline is one of the components of
phosphatidylcholine, a component of the phospholipids found in
all cell membranes.61 In cancers, rapid cell duplication results in
active uptake of choline. 18F-Fluorocholine has a longer half-life
than 11C-acetate, which allows for its use in a greater number of
centres and also enables delayed imaging, improving the quality of
images obtained.61 HCCs are significant accumulators of choline
as a result of rapid cell turnover. At present, only small numbers of
patients have been assessed using 18F-Fluorocholine PET-CT in
comparison to standard 18F-FDG PET-CT. The results suggest
improved accuracy of 18F-Fluorocholine PET-CT in detecting
both intrahepatic and recurrent extrahepatic HCCs in 12 patients
assessed using these techniques.61 No large-scale study comparing
18F-Fluorocholine PET-CT with MRI or CT imaging is presently
available in the literature.
A single-centre experience of dual tracer 11C-acetate and 18F-
FDG PET-CT has been reported in the evaluation of metastatic
HCC.62 Dual tracer imaging was found to be approximately 70%
sensitive with a change in management initiated in 19% of
studied patients as a result of the imaging acquired.62
Other studies reporting the use of 18F-FDG PET-CT are largely
limited to case reports detailing its use in detecting omental
HCC recurrence63 or portal vein tumour thrombus.64 18F-FDG
PET-CT has been reported as being more accurate than CT
alone in the detection of recurrent intrahepatic HCC after tran-
scatheter arterial embolization (TACE) or radiofrequency abla-
tion (90.9% accuracy vs. 45.4% respectively) in a series of 13
patients.65 However, for the most part, current PET-CT technol-
ogy limits its application in the assessment of hepatocellular
carcinoma.
PET-CT and gall-bladder cancer and
cholangiocarcinoma
Only three studies were found detailing PET-CT in the staging
and surveillance of cholangiocarcinomas and gallbladder cancers,
the data are summarised in Table 3.66–73 There are not enough data
to make a meaningful comparison between PET-CT and MRI in
the imaging of cholangiocarcinomas, but most studies reported
PET-CT to be better than conventional CT scanning in the assess-
ment of primary lesions, and in particular, in the detection of
distant unexpected metastatic spread including regional lymph
nodes and more distant sites of metastases. Of note, is a marked
reduction in sensitivity and specificity of PET-CT in the charac-
terization of extrahepatic versus intrahepatic cholangiocarcino-
mas.70 PET-CT has also been shown to be of some value in
differentiating between benign and malignant hilar strictures.72
These encouraging preliminary reports need consolidation from
other centres before firm conclusions can be drawn.Ta
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PET-CT in and pancreatic cancer
Pancreatic adenocarcinoma
PET imaging alone has a reported sensitivity of 82% to 100% and
a specificity of 67% to 100% in the diagnosis of pancreatic
adenocarcinoma.74–76 Hypoxia in CLMs has been postulated in
being a cause for poor 18F-FDG uptake.28 Pancreatic adenocarci-
nomas, in particular, show evidence of hypoxic tumour cores,77
which may result in poor uptake of 18F-FDG and render their
characterization by PET-CT sub-optimal. In addition, back-
ground inflammatory changes within the pancreas (such as
chronic pancreatitis) may also result in increased 18F-FDG uptake,
rendering the detection of small pancreatic lesions problematic.78
18F-fluorothymidine (FLT) has also been proposed as new
radiotracer which assesses cells undergoing active proliferation.
There is one report of 18FLT used in a series of five patients with
pancreatic adenocarcinoma compared with standard 18F-FDG
PET-CT.71 Despite the small numbers of patients, the results do
not suggest any advantage over 18F-FDG (Table 1).
The paucity of relevant data suggests that PET-CT is not cur-
rently routinely used in the diagnosis or surveillance of pancreatic
adenocarcinoma. Prospective data of PET-CT in detecting pan-
creatic lesions have shown it to be no worse than traditional
investigative modalities such as endoscopic retrograde cholangio-
pancreatography (ERCP), endoscopic or abdominal USS.73 Inter-
estingly, no comparison with conventional CT was made in the
study (Table 3), but other prospective data do not suggest a sig-
nificant advantage of PET-CT compared with multi-row detector
CT in the diagnosis, staging or surveillance of pancreatic
tumours.66 A prospective study by Heinrich et al. reported
PET-CT to have broadly equivalent sensitivities to conventional
CT in the diagnosis of the primary lesion but improved specificity
(Table 3). For distant metastases, PET-CT was more sensitive than
conventional CT and changed management plans for 16% of
people (deemed resectable after conventional staging), which
equated to a cost saving of $62,912 per patient.67 The cost-
effectiveness analysis provided by the authors, has been subse-
quently criticized as confusing and the point has been raised that
a negative PET-CT does not rule out cancer with any degree of
certainty, although a positive PET-CT is of value in the assessment
of these lesions.79
The remaining literature describing PET-CT in the evaluation
of pancreatic cancer consists of case reports detailing isolated
experiences of PET-CT in detecting distant metastatic spread80 or
tumour thrombus81 and proposing the use of PET-CT in evalua-
tion treatment response of pancreatic tumours after radio-
therapy.82 These manuscripts are mentioned for completeness, but
are not included in Table 3.
Cystic lesions of the pancreas
Cystic lesions of the pancreas represent a difficult problem to the
hepatobiliary surgeon in excluding premalignant or malignant
lesions from benign. A wide range of different investigations
are generally required including cross-sectional imaging,
laparoscopic/endoscopic ultrasound and cytological/biochemical
analysis of cyst fluid to obtain a diagnosis. The decision to resect
such lesions may, on occasion, be made on size alone if no clear-
cut classification can be made pre-operatively.83 The additional
physiological information provided by PET-CT could prove a
valuable addition to the multi-modality assessment currently
employed. In this context, PET-CT has been found to more sen-
sitive than conventional CT, although specificities were not sig-
nificantly different.84 PET in isolation has also been described, in
the form of a case report of a single patient, to detect a focus of
malignancy in intraductal papillary mucinous tumours (IPMTs),
but no other data are present to support the use of PET-CT for
pancreatic cystic lesions.85
Neuroendocrine tumours
Neuroendocrine tumours are a broad group of tumours derived
from endocrine cells, with the capacity to produce a variety of
biogenic amines and polypeptides. The classification of neuroen-
docrine tumours is dependent upon the size of the tumour and
proliferation rate.86 Three classes of neuroendocrine tumours are
described which are Type 1a (well-differentiated; Ki67 <2%), Type
1b (well-differentiated; Ki67 2 to 10%) and Type II (poorly dif-
ferentiated).86 In spite of this, the anatomical origin of neuroen-
docrine tumours determines the nature and type of resection and
neuroendocrine tumours (NET) represent a consistent (albeit
small) component of the referral load for the hepatobiliary
surgeon. An overview of PET-CT imaging in the investigation of
all NETs will be presented, where possible data specifically related
to NETs of hepatobiliary origin will be included.
An important feature of NETs is that because of their functional
nature, they may present with marked symptoms early, before the
primary tumour is large enough to be found with conventional
imaging, for this reason functional imaging may be the sole means
of accurate diagnosis and localizing a small lesion. Four different
types of radiotracers have been employed in the characterization
of NETs. The most common is 18F-FDG, with the other radiotrac-
ers being developed to target specific functional properties of
NETs. Well-differentiated NETs are indolent tumours with a low
metabolic turnover and so may not be imaged clearly on standard
18F-FDG radiotracer PET-CTs. In contrast, fast-growing and
poorly differentiated tumours may lose their functional ability
and thus be less ‘visible’ with the novel radiotracer techniques
detailed below. Hence, a combination of glucose metabolism
probes and functional NET probes may compliment each other in
detecting NETs and providing information regarding the degree
of tumour differentiation.
Some NETs have the ability to take up and decarboxylate amine
precursors, such as dihydroxyphenylalanine (DOPA) and hydrox-
ytryptophane, leading to their alternative eponym of amine
precursor uptake and decarboxylation (APUD) tumours.87
Radiolabelled amine precursors can thus be employed such
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as 11C-hydroxytryptophane (HT), 18F-dihydroxyphenylalanine
(DOPA) or 18F-fluorodopamine.88 NETs over-express a variety of
peptide receptors including somatostatin receptors, which has
been previously exploited in somatostatin receptor scintigraphy.A
more recent development is 68Gadolinium-labelled somatostatin
analogues which can be detected with PET cameras, leading to
higher resolution of small NETs.88 Finally, 11C-hydroxyephedinre
or 11C-metomidate can also be employed, which are concentrated
in adrenal tissues in particular. Both radiotracers are accumulated
as a consequence of the synthesis of cortisol and aldosterone in the
adrenal cortex.88
It is not possible to compare radiotracer efficacy used in PET-
CTs for NETs, because of the wide range of different compounds
currently in usage. Overall, the data show that PET-CT is consis-
tently more accurate and sensitive than CT alone, MRI and
somatostatin scintigraphy (Table 4).89–93 In the assessment of liver
lesions, PET-CT would not appear to be significantly better than
MRI scanning,93 but is more accurate in the detection of osseous
disease or lymph node disease. MRI and PET fusion was found by
one study to be better than CT, PET-CT or MRI alone in the
detection of liver, lymph node and osseous disease with detection
rates of 100%, 97.3% and 100%, respectively.93 It is likely that a
combination of PET-CT radiotracers, used in conjunction with
conventional imaging, may offer the best yield of clinical infor-
mation. Dual tracer PET-CT has been shown to offer information
on tumour staging and to improve overall sensitivity from 66%
and 82% (used independently) to 92%.90
Conclusion
Since its introduction, PET-CT has been employed in the charac-
terization of a wide range of malignancies. The indications and
relative indications for PET-CT are summarized in Fig. 3. It is
probable that some of these indications may change with time.
PET-CT is now an accepted part of staging and diagnosis for
primary colorectal cancer and CLMs. However, it still not clear if
PET-CT should be used routinely for such patients or only after
discussion at multidisciplinary team (MDT). There is growing
evidence of the efficacy of PET-CT in the evaluation of pancreatic
masses and neuroendocrine tumours, but at present more clinical
data are required before PET-CT becomes a routine investigation
in the assessment of these malignancies. The data for PET-CT in
the context of cholangiocarcinoma and in particular, in diagnosis
and staging of gallbladder cancer are insufficient at present to
allow for a conclusive recommendation to be made. Finally,
PET-CTwould appear to have the least impact in themanagement
for hepatocellular cancer, although, with the development of dual-
tracer PET-CT, this may change in the future.
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